We only have this paper's title and publication details.
Read it at the sourceClinical observation identifies tumor lysis syndrome triggered by elranatamab in multiple myeloma, suggesting cautious monitoring.
TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies.
No takes yet. Share an insight, caveat, or question.
Milanesio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: